Market Assessment, Asthma Emerging Therapies Asthma & COPD Salmeterol & Fluticasone Generic Wave 2 US Report

Asthma - Emerging Therapies - Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)
- Asthma and COPDu00a0Emerging Therapies Salmeterol / Fluticasone Genericu00a0US Wave 2 (October 2019)

Ajay Puri, M.B.A.

Ajay Puri, M.B.A. (Pharma.), Senior Healthcare Research & Data Analyst, Immune and Inflammation. He has expertise in Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus. Prior to joining Clarivate, he worked as a knowledge management associate at ZS Associates, where he conducted competitive assessment, company and product profiling, and other projects. He holds a bachelor’s degree in pharmacy and an M.B.A. in marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Asthma – Emerging Therapies – Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Table of contents

Related Market Assessment Reports

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)